首頁 > 市場調查報告書 > 製藥

神經疾病

全球腦脊髓炎市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1408994

全球腦脊髓炎市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Encephalomyelitis Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 247 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2030 年，全球腦脊髓炎市場的市場規模將從 2022 年的 212.8 億美元達到近 348.8 億美元，2023-2030 年研究期間CAGR為 6.37%。

腦脊髓炎是指大腦（腦）和脊髓（脊髓炎）的發炎。這可能是由於感染、自體免疫疾病和其他發炎過程引起的。這種情況可能是急性的，即突然發生並伴隨嚴重症狀，也可能是慢性的，涉及長期或復發性發炎。

市場動態

推動腦脊髓炎理解和治療進步和發展的因素包括神經學和免疫學方面正在進行的研究進展。這些努力有助於改善診斷工具和治療方案。提高對各種形式腦脊髓炎（例如 ADEM 或 ME/CFS）的認知措施在促進早期診斷和介入方面發揮著至關重要的作用。醫學影像和診斷工具的技術創新進一步增強了準確診斷和監測腦脊髓炎的能力，塑造了研究和臨床實踐的方向。醫療保健專業人員、研究人員、患者權益團體和製藥公司之間的合作努力促進了知識和資源的交流，促進了該領域的進步。腦脊髓炎新療法或治療方法的發現和開發有助於增加對醫療和製藥領域的興趣和投資，從而促進管理這種複雜疾病的進步。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球腦脊髓炎市場的每個細分市場進行了包容性評估。腦脊髓炎產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲腦脊髓炎市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。腦脊髓炎市場的主要參與者包括Oncomed Pharmaceuticals、輝瑞公司、Immunomedics、武田製藥、艾伯維公司、楊森生物技術公司、阿斯特捷利康公司、禮來公司、羅氏公司、諾華公司、拜耳公司、默克公司、安進公司、Spectrum Pharmaceuticals Inc.、葛蘭素史克公司、賽諾菲公司及百時美施貴寶公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：腦脊髓炎公司的競爭格局

腦脊髓炎市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
Oncomed Pharmaceuticals

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Immunomedics

公司簡介
公司收入
產品
最近的發展

Takeda Pharmaceuticals

公司簡介
公司收入
產品
最近的發展

AbbVie Inc.

公司簡介
公司收入
產品
最近的發展

Janssen Biotech Inc.

公司簡介
公司收入
產品
最近的發展

AstraZeneca Plc.

公司簡介
公司收入
產品
最近的發展

Eli Lilly and Company

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche Ltd.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Bayer AG

公司簡介
公司收入
產品
最近的發展

Merck & Co. Inc.

公司簡介
公司收入
產品
最近的發展

Amgen Inc.

公司簡介
公司收入
產品
最近的發展

Spectrum Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

GlaxoSmithKline Plc.

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

Bristol-Myers Squibb Company

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113252

The global demand for Encephalomyelitis Market is presumed to reach the market size of nearly USD 34.88 BN by 2030 from USD 21.28 BN in 2022 with a CAGR of 6.37% under the study period 2023 - 2030.

Encephalomyelitis refers to the inflammation of both the brain (encephalo) and the spinal cord (myelitis). This may be caused due to infections, autoimmune disorders, and other inflammatory processes. This condition can be acute, meaning it occurs suddenly with severe symptoms, or it can be chronic, involving long-term or recurrent inflammation.

MARKET DYNAMICS

The factors driving progress and developments in the understanding and management of encephalomyelitis include ongoing research advances in neurology and immunology. These efforts contribute to improved diagnostic tools and treatment options. Increased awareness initiatives focused on various forms of encephalomyelitis, such as ADEM or ME/CFS, play a vital role in promoting early diagnosis and intervention. Technological innovations in medical imaging and diagnostic tools further enhance the ability to accurately diagnose and monitor encephalomyelitis, shaping the direction of research and clinical practices. Collaborative efforts among healthcare professionals, researchers, patient advocacy groups, and pharmaceutical companies facilitate the exchange of knowledge and resources, fostering progress in the field. The discovery and development of new treatments or therapeutic approaches for encephalomyelitis contribute to increased interest and investment in the medical and pharmaceutical sectors, promoting advancements in managing this complex medical condition.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of encephalomyelitis. The growth and trends of encephalomyelitis industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the encephalomyelitis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By End-Users

Clinics
Hospitals
Others

By Treatment

Surgery
Plasmapheresis
Drug Treatment
Others

By Type

Equine Encephalomyelitis
Associated Encephalomyelitis
AntiMOG
Encephalomyelitis Disseminata
Acute Disseminated Encephalomyelitis
AIDS-Related Encephalomyelitis
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Encephalomyelitis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Encephalomyelitis market include Oncomed Pharmaceuticals, Pfizer Inc., Immunomedics, Takeda Pharmaceuticals, AbbVie Inc., Janssen Biotech, Inc., AstraZeneca Plc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Merck & Co. Inc., Amgen Inc., Spectrum Pharmaceuticals Inc., GlaxoSmithKline Plc., Sanofi, and Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ENCEPHALOMYELITIS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By End-Users
- 3.7.2 Market Attractiveness Analysis By Treatment
- 3.7.3 Market Attractiveness Analysis By Type
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY END-USERS

5.1 Overview by End-Users
5.2 Historical and Forecast Data
5.3 Analysis by End-Users
5.4 Clinics Historic and Forecast Sales by Regions
5.5 Hospitals Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY TREATMENT

6.1 Overview by Treatment
6.2 Historical and Forecast Data
6.3 Analysis by Treatment
6.4 Surgery Historic and Forecast Sales by Regions
6.5 Plasmapheresis Historic and Forecast Sales by Regions
6.6 Drug Treatment Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY TYPE

7.1 Overview by Type
7.2 Historical and Forecast Data
7.3 Analysis by Type
7.4 Equine Encephalomyelitis Historic and Forecast Sales by Regions
7.5 Associated Encephalomyelitis Historic and Forecast Sales by Regions
7.6 AntiMOG Historic and Forecast Sales by Regions
7.7 Encephalomyelitis Disseminata Historic and Forecast Sales by Regions
7.8 Acute Disseminated Encephalomyelitis Historic and Forecast Sales by Regions
7.9 AIDS-Related Encephalomyelitis Historic and Forecast Sales by Regions
7.10. Others Historic and Forecast Sales by Regions

8 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ENCEPHALOMYELITIS COMPANIES

9.1. Encephalomyelitis Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF ENCEPHALOMYELITIS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Oncomed Pharmaceuticals
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Pfizer Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Immunomedics
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Takeda Pharmaceuticals
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. AbbVie Inc.
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Janssen Biotech Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. AstraZeneca Plc.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Eli Lilly and Company
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. F. Hoffmann-La Roche Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Novartis AG
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Bayer AG
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
10.14. Merck & Co. Inc.
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments
10.15. Amgen Inc.
- 10.15.1. Company Overview
- 10.15.2. Company Revenue
- 10.15.3. Products
- 10.15.4. Recent Developments
10.16. Spectrum Pharmaceuticals Inc.
- 10.16.1. Company Overview
- 10.16.2. Company Revenue
- 10.16.3. Products
- 10.16.4. Recent Developments
10.17. GlaxoSmithKline Plc.
- 10.17.1. Company Overview
- 10.17.2. Company Revenue
- 10.17.3. Products
- 10.17.4. Recent Developments
10.18. Sanofi
- 10.18.1. Company Overview
- 10.18.2. Company Revenue
- 10.18.3. Products
- 10.18.4. Recent Developments
10.19. Bristol-Myers Squibb Company
- 10.19.1. Company Overview
- 10.19.2. Company Revenue
- 10.19.3. Products
- 10.19.4. Recent Developments